1. Home
  2. MTEN vs XCUR Comparison

MTEN vs XCUR Comparison

Compare MTEN & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mingteng International Corporation Inc. Ordinary Shares

MTEN

Mingteng International Corporation Inc. Ordinary Shares

BUY

Current Price

$0.85

Market Cap

7.7M

Sector

Industrials

ML Signal

BUY

Logo Exicure Inc.

XCUR

Exicure Inc.

HOLD

Current Price

$1.17

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTEN
XCUR
Founded
2015
2011
Country
China
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
9.2M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
MTEN
XCUR
Price
$0.85
$1.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.1M
15.6K
Earning Date
10-30-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 83.37
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$44.02
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.02
$0.94
52 Week High
$9.52
$9.48

Technical Indicators

Market Signals
Indicator
MTEN
XCUR
Relative Strength Index (RSI) 38.90 41.42
Support Level $0.85 $1.05
Resistance Level $1.25 $1.48
Average True Range (ATR) 0.09 0.10
MACD -0.01 0.01
Stochastic Oscillator 11.88 39.59

Price Performance

Historical Comparison
MTEN
XCUR

About MTEN Mingteng International Corporation Inc. Ordinary Shares

Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides an extensive product lineup, including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in the automobile, construction machinery, and other manufacturing industries.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: